• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Azar Alex M Ii

    9/26/25 5:04:57 PM ET
    $GH
    Medical Specialities
    Health Care
    Get the next $GH alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Azar Alex M II

    (Last) (First) (Middle)
    3100 HANOVER STREET

    (Street)
    PALO ALTO CA 94304

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Guardant Health, Inc. [ GH ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    09/12/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy) $54.895 09/12/2025 A 10,532 (1) 09/12/2035 Common Stock 10,532 $0 10,532 D
    Restricted Stock Units $0 09/12/2025 A 6,604 (2) (3) Common Stock 6,604 $0 6,604 D
    Explanation of Responses:
    1. The stock option was granted on September 12, 2025 and vests over a four-year period. 25% of the shares subject to such award will vest on the one-year anniversary of September 12, 2025 and the remaining 75% vests monthly for the three-year period thereafter.
    2. The restricted stock unit award was granted on September 12, 2025 and vests over a four-year period. 25% of the shares subject to such award will vest on the one-year anniversary of September 12, 2025 and the remaining 75% vests monthly for the three-year period thereafter.
    3. Not applicable for Restricted Stock Units.
    Remarks:
    /s/ John G. Saia, as attorney-in-fact for Alex M. Azar II 09/26/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $GH alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GH

    DatePrice TargetRatingAnalyst
    9/25/2025$75.00Peer Perform → Outperform
    Wolfe Research
    9/22/2025$72.00Overweight
    Wells Fargo
    4/10/2025$55.00Outperform
    Mizuho
    1/23/2025$60.00Overweight
    Barclays
    6/28/2024$36.00Neutral → Buy
    Guggenheim
    6/3/2024$32.00Buy
    Jefferies
    4/24/2024$28.00Buy
    Craig Hallum
    12/14/2023Neutral
    Guggenheim
    More analyst ratings

    $GH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guardant Health upgraded by Wolfe Research with a new price target

    Wolfe Research upgraded Guardant Health from Peer Perform to Outperform and set a new price target of $75.00

    9/25/25 8:22:52 AM ET
    $GH
    Medical Specialities
    Health Care

    Wells Fargo resumed coverage on Guardant Health with a new price target

    Wells Fargo resumed coverage of Guardant Health with a rating of Overweight and set a new price target of $72.00

    9/22/25 8:30:36 AM ET
    $GH
    Medical Specialities
    Health Care

    Mizuho initiated coverage on Guardant Health with a new price target

    Mizuho initiated coverage of Guardant Health with a rating of Outperform and set a new price target of $55.00

    4/10/25 12:41:47 PM ET
    $GH
    Medical Specialities
    Health Care

    $GH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Azar Alex M Ii

    4 - Guardant Health, Inc. (0001576280) (Issuer)

    9/26/25 5:04:57 PM ET
    $GH
    Medical Specialities
    Health Care

    New insider Azar Alex M Ii claimed no ownership of stock in the company (SEC Form 3)

    3 - Guardant Health, Inc. (0001576280) (Issuer)

    9/26/25 5:03:33 PM ET
    $GH
    Medical Specialities
    Health Care

    Director Hidalgo Medina Manuel converted options into 232 shares, increasing direct ownership by 27% to 1,083 units (SEC Form 4)

    4 - Guardant Health, Inc. (0001576280) (Issuer)

    9/18/25 4:33:55 PM ET
    $GH
    Medical Specialities
    Health Care

    $GH
    SEC Filings

    View All

    Guardant Health Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Guardant Health, Inc. (0001576280) (Filer)

    9/24/25 7:50:17 AM ET
    $GH
    Medical Specialities
    Health Care

    SEC Form 144 filed by Guardant Health Inc.

    144 - Guardant Health, Inc. (0001576280) (Subject)

    9/17/25 4:17:32 PM ET
    $GH
    Medical Specialities
    Health Care

    Guardant Health Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Guardant Health, Inc. (0001576280) (Filer)

    9/15/25 4:11:12 PM ET
    $GH
    Medical Specialities
    Health Care

    $GH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    FDA Approves Guardant360® CDx as Companion Diagnostic for Eli Lilly and Company's Inluriyo™ (imlunestrant) for Treatment of ESR1-mutated Advanced Breast Cancer

    This marks the second FDA-approved indication for Guardant360 CDx as a companion diagnostic in breast cancer treatment ESR1 mutations are present in 40% of HR+, HER2- advanced breast cancers Guardant Health, Inc. (NASDAQ: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved its Guardant360® CDx as a companion diagnostic to identify advanced breast cancer patients with ESR1 mutations who may benefit from Eli Lilly and Company's Inluriyo (imlunestrant). Guardant360 CDx was approved in conjunction with Inluriyo for the treatment of adults with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-ne

    9/29/25 8:05:00 AM ET
    $GH
    Medical Specialities
    Health Care

    Guardant Health and Quest Diagnostics Announce Strategic Collaboration to Broaden Access to Guardant's Shield™ Blood-based Screening Test in the United States

    Collaboration to enable streamlined and accelerated access to Shield blood-based colorectal cancer screening test across Quest's vast network Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, and Quest Diagnostics (NYSE:DGX), a leader in diagnostic information services, today announced a broad strategic collaboration to make Guardant's Shield™ blood-based screening test available to physicians and patients served by Quest in the United States. Shield is the first and only blood test to receive full FDA approval as a primary screening option for colorectal cancer in average-risk adults aged 45 and older. Through a multi-year agreement, Quest's provider clients that

    9/24/25 8:05:00 AM ET
    $DGX
    $GH
    Medical Specialities
    Health Care

    Alex M. Azar II Joins Guardant Health Board of Directors

    Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the appointment of Alex M. Azar II to its board of directors, effective immediately. As the 24th Secretary of the U.S. Department of Health and Human Services (HHS), Secretary Azar had oversight and management of agencies critical to all Americans' health care including the Centers for Medicare and Medicaid Services, the Food and Drug Administration, and the Center for Disease Control and Prevention. "We're honored to welcome Secretary Azar to Guardant's board," said Helmy Eltoukhy, chairman and co-CEO of Guardant Health. "Secretary Azar has served at the senior-most levels of government as well as th

    9/15/25 4:07:00 PM ET
    $GH
    Medical Specialities
    Health Care

    $GH
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    July 30, 2024 - FDA Roundup: July 30, 2024

    For Immediate Release: July 30, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA is announcing the fiscal year (FY) 2025 user fee rates for importers approved to participate in the Voluntary Qualified Importer Program (VQIP) and accreditation and certification bodies interested in participating in the Accredited Third-Party C

    7/30/24 3:38:18 PM ET
    $GH
    Medical Specialities
    Health Care

    May 28, 2021 - FDA Approves First Targeted Therapy for Lung Cancer Mutation Previously Considered Resistant to Drug Therapy

    For Immediate Release: May 28, 2021 Today, the U.S. Food and Drug Administration approved Lumakras (sotorasib) as the first treatment for adult patients with non-small cell lung cancer whose tumors have a specific type of genetic mutation called KRAS G12C and who have received at least one prior systemic therapy. This is the first approved targeted therapy for tumors with any KRAS mutation, which accounts for ap

    5/28/21 1:05:48 PM ET
    $AMGN
    $GH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical Specialities

    May 21, 2021 - FDA Approves First Targeted Therapy for Subset of Non-Small Cell Lung Cancer

    For Immediate Release: May 21, 2021 Today, the U.S. Food and Drug Administration approved Rybrevant (amivantamab-vmjw) as the first treatment for adult patients with non-small cell lung cancer whose tumors have specific types of genetic mutations: epidermal growth factor receptor (EGFR) exon 20 insertion mutations. The FDA also approved the Guardant360 CDx (Guardant Health Inc.) as a companion diagnostic for Ry

    5/21/21 12:50:51 PM ET
    $JNJ
    $GH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities

    $GH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Kalia Kumud bought $38,963 worth of shares (2,187 units at $17.82), increasing direct ownership by 21% to 12,722 units (SEC Form 4)

    4 - Guardant Health, Inc. (0001576280) (Issuer)

    3/19/24 5:29:06 PM ET
    $GH
    Medical Specialities
    Health Care

    $GH
    Financials

    Live finance-specific insights

    View All

    Guardant Health Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

    Revenue growth of 31% broadly driven by strong performance across Oncology, Screening, and Biopharma & Data Raises 2025 revenue guidance to $915 to $925 million, representing growth of 24% to 25% Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today reported financial results for the quarter ended June 30, 2025. Second Quarter 2025 Financial Highlights For the three-month period ended June 30, 2025, as compared to the same period of 2024: Reported total revenue of $232.1 million, an increase of 31%, driven by: Oncology revenue of $158.7 million, an increase of 22%, and approximately 64,000 oncology tests, an increase of 30% Screening revenue of $14.8

    7/30/25 4:05:00 PM ET
    $GH
    Medical Specialities
    Health Care

    Guardant Health to Report Second Quarter 2025 Financial Results on July 30, 2025

    Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2025 after market close on Wednesday, July 30, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.guardanthealth.com. The webcast will be archived and available for replay after the event. About Guardant Health Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012,

    7/14/25 8:00:00 AM ET
    $GH
    Medical Specialities
    Health Care

    Guardant Health Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

    Revenue growth of 21% broadly driven by strong performance across oncology, screening, and biopharma & data Raises 2025 revenue guidance to $880 to $890 million, representing growth of 19% to 20% Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today reported financial results for the quarter ended March 31, 2025. First Quarter 2025 Financial Highlights For the three-month period ended March 31, 2025, as compared to the same period of 2024: Reported total revenue of $203.5 million, an increase of 21%, driven by: Oncology revenue of $150.6 million, an increase of 20%, and approximately 59,000 oncology tests, an increase of 25% Screening revenue of $5.7 milli

    4/30/25 4:05:00 PM ET
    $GH
    Medical Specialities
    Health Care

    $GH
    Leadership Updates

    Live Leadership Updates

    View All

    Alex M. Azar II Joins Guardant Health Board of Directors

    Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the appointment of Alex M. Azar II to its board of directors, effective immediately. As the 24th Secretary of the U.S. Department of Health and Human Services (HHS), Secretary Azar had oversight and management of agencies critical to all Americans' health care including the Centers for Medicare and Medicaid Services, the Food and Drug Administration, and the Center for Disease Control and Prevention. "We're honored to welcome Secretary Azar to Guardant's board," said Helmy Eltoukhy, chairman and co-CEO of Guardant Health. "Secretary Azar has served at the senior-most levels of government as well as th

    9/15/25 4:07:00 PM ET
    $GH
    Medical Specialities
    Health Care

    Guardant Health Joins Forces With Dak Prescott's Faith Fight Finish Foundation and Feist-Weiller Cancer Center's Partners in Wellness to Boost Colon Cancer Screening in Underserved Communities

    Foundation's grant to mobile cancer screening program in Louisiana allows individuals to be screened with Guardant's Shield™ blood test in their own community Mobile screening events to be held during Colorectal Cancer Awareness Month (March) throughout northern and central Louisiana Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced a collaboration with Dak Prescott's Faith Fight Finish Foundation and the mobile cancer screening program, Partners in Wellness, an initiative of LSU Health Shreveport and Ochsner LSU Health—Feist-Weiller Cancer Center, to increase colorectal cancer screening rates in northern and central Louisiana. This press release

    3/5/25 8:05:00 AM ET
    $GH
    Medical Specialities
    Health Care

    Roberto A. Mignone Joins Guardant Health Board of Directors

    Guardant Health, Inc. (NASDAQ:GH), a pioneer in precision oncology, today announced the appointment of Roberto A. Mignone to its board of directors, effective immediately. Mr. Mignone is the Founder and Managing Partner of Bridger Management LLC, an investment management firm founded in 2000 and specializing in long-term equity strategies. "We are fortunate to welcome Roberto Mignone to our board of directors, bringing his healthcare industry expertise, long-term vision, and business acumen to our company," said Helmy Eltoukhy, chairman and co-CEO of Guardant Health. "We look forward to Mr. Mignone's perspective as we strengthen our product offerings across the continuum of care, and look

    10/24/24 5:05:00 PM ET
    $GH
    Medical Specialities
    Health Care

    $GH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Guardant Health Inc.

    SC 13G - Guardant Health, Inc. (0001576280) (Subject)

    11/13/24 7:34:17 PM ET
    $GH
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Guardant Health Inc.

    SC 13G - Guardant Health, Inc. (0001576280) (Subject)

    11/8/24 10:46:38 AM ET
    $GH
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Guardant Health Inc.

    SC 13G/A - Guardant Health, Inc. (0001576280) (Subject)

    7/5/24 10:32:48 AM ET
    $GH
    Medical Specialities
    Health Care